Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZR Trial: Denosumab vs Zoledronate Following Romosozumab in Osteoporosis
jRCT1051220150Not yet recruiting
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Randomised trial in osteoporosis comparing Denosumab after romosozumab with Zoledronate after romosozumab (2 arms). Primary endpoints: Bone mineral density at lumbar spine and Bone mineral density at total hip. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
denosumabzoledronateromosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on jRCT1051220150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051220150.